Nicotine delivery and users' reactions to Juul compared with cigarettes and other e-cigarette products.
E-cigarettes
Juul
nicotine
nicotine delivery
pharmacokinetic
tobacco
Journal
Addiction (Abingdon, England)
ISSN: 1360-0443
Titre abrégé: Addiction
Pays: England
ID NLM: 9304118
Informations de publication
Date de publication:
06 2020
06 2020
Historique:
received:
22
03
2019
revised:
01
07
2019
accepted:
09
12
2019
pubmed:
30
1
2020
medline:
19
3
2021
entrez:
30
1
2020
Statut:
ppublish
Résumé
To assess the pharmacokinetic (PK) profile of, and users' reactions to, Juul (59 mg nicotine/ml) as an indication of its therapeutic and dependence potential. Cross-over, within-subjects study in which participants attended after overnight abstinence on separate sessions and smoked a cigarette or used Juul or eight other types of e-cigarettes (EC) ad libitum for 5 minutes. The Juul product used was the version available in the United States that has more nicotine in the e-liquid than the one available in the European Union. Laboratory setting in the United Kingdom. Twenty dual users (smokers who also vape) provided data on Juul and cigarettes, with eight also providing data on other EC products. At each session, number of puffs taken was counted during the 5-minute product use period and blood samples were taken at baseline and at 2, 4, 6, 8, 10 and 30 minutes after starting smoking/vaping and analysed for nicotine. Participants also monitored their urges to smoke and rated the products on a range of characteristics. Juul's PK profile was close to the PK profile of cigarettes [maximum concentration (C Juul's PK profile and user ratings suggest that it could be more effective than other EC products in helping smokers to quit smoking, but it may also have a higher potential to generate regular use in non-smokers.
Identifiants
pubmed: 31994254
doi: 10.1111/add.14936
pmc: PMC7318270
doi:
Substances chimiques
Nicotine
6M3C89ZY6R
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1141-1148Subventions
Organisme : Cancer Research UK
ID : C49913/A25756
Pays : United Kingdom
Informations de copyright
© 2020 The Authors. Addiction published by John Wiley & Sons Ltd on behalf of Society for the Study of Addiction.
Références
Tob Control. 2019 Jan;28(1):110-112
pubmed: 29654121
Nicotine Tob Res. 2013 Mar;15(3):622-32
pubmed: 22990226
Tob Control. 2019 Nov;28(6):603-609
pubmed: 30377241
Psychopharmacology (Berl). 1987;92(4):424-30
pubmed: 3114794
Addiction. 2015 Jul;110 Suppl 2:19-22
pubmed: 26042563
Psychopharmacology (Berl). 1997 Apr;130(4):352-61
pubmed: 9160851
Prev Med. 2007 Mar;44(3):230-4
pubmed: 17207524
J Chromatogr B Analyt Technol Biomed Life Sci. 2011 Feb 1;879(3-4):267-76
pubmed: 21208832
Nicotine Tob Res. 2018 Nov 15;20(12):1427-1433
pubmed: 29126298
N Engl J Med. 2019 Feb 14;380(7):629-637
pubmed: 30699054
Cochrane Database Syst Rev. 2012 Nov 14;11:CD000146
pubmed: 23152200
N Engl J Med. 2018 Sep 20;379(12):1099-1102
pubmed: 30134127
Nicotine Tob Res. 2012 Oct;14(10):1127-39
pubmed: 22377934
Addiction. 2018 May;113(5):805-816
pubmed: 29377409
JAMA. 2018 Oct 2;320(13):1379-1380
pubmed: 30285167
Addiction. 2020 Jun;115(6):1141-1148
pubmed: 31994254
Psychopharmacology (Berl). 2018 Apr;235(4):1083-1092
pubmed: 29306962
JAMA. 1988 Sep 16;260(11):1593-6
pubmed: 3411739
Comput Methods Programs Biomed. 2010 Sep;99(3):306-14
pubmed: 20176408
Nicotine Tob Res. 2016 May;18(5):509-23
pubmed: 26508396
Psychopharmacology (Berl). 2000 Apr;149(3):198-202
pubmed: 10823399
Addiction. 2014 Nov;109(11):1801-10
pubmed: 25078252
Nicotine Tob Res. 2016 Jan;18(1):102-3
pubmed: 26250882
Psychopharmacology (Berl). 2017 Mar;234(5):773-779
pubmed: 28070620
Nicotine Tob Res. 2020 Apr 21;22(5):843-847
pubmed: 30312465